(lp0
S'aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors GlobeNewswire  - Apr 10, 2017 SAN DIEGO, April 10, 2017  -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the&nbsp;...aTyr Pharma Inc  Stake Held by Fmr LLC - BNB Daily '
p1
aS'aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors PR Newswire  - Apr 3, 2017 SAN DIEGO, April 3, 2017 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the appointment of&nbsp;...'
p2
aS"aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference Yahoo Finance - Mar 29, 2017 SAN DIEGO, March 29, 2017  -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's&nbsp;..."
p3
aS'aTyr Pharma Inc. LIFE  Wall Street Journal - Feb 12, 2011 News aTyr Pharma Inc.LIFE. Significant News Only. 04/03/17; Press Release. aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors.'
p4
aS'aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference PR Newswire  - Dec 9, 2016 SAN DIEGO, Dec. 9, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior&nbsp;...'
p5
aS'aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris in its ... PR Newswire  - Mar 30, 2016 SAN DIEGO, March 30, 2016 /PRNewswire/ -- aTyr Pharma, Inc.  a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced results from a&nbsp;...'
p6
aS'aTyr Pharma Enters into $20 Million Credit Facility PR Newswire  - Nov 21, 2016 SAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced it has entered into a&nbsp;...'
p7
aS'aTyr Pharma Receives US FDA Orphan Drug Designation for the Treatment of Limb ... PR Newswire  - Feb 28, 2017 SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product&nbsp;...Resolaris an Orphan Drug for limb girdle muscular dystrophy; aTyr up 19% - Seeking AlphaResolaris Granted Orphan Drug Status for Rare Genetic Myopathy - Monthly Prescribing Reference '
p8
aS"San Diego's aTyr Pharma Raises Total Proceeds of $75M in IPO Xconomy - May 7, 2015 Shares of San Diego-based aTyr Pharma are expected to begin trading on the Nasdaq market tomorrow morning, after the company priced its IPO late today, selling nearly 5.4 million shares at $14 a share."
p9
aS'BMO Sets $8 Target for Atyr Pharma  Investopedia - Oct 11, 2016 The firm said it will provide additional information on resolaris in December (see also: Gershman of aTyr Pharma to Speak on Muscular Dystrophy.'
p10
a.